Uroplakin II (Clone: BC21) 0,1 mL
Uroplakin II is a 15 kDa protein component of urothelial plaques. Studies
have shown Uroplakin II mRNA was highly specific and was expressed in both
bladder cancer tissues and peripheral blood of patients with primary and
metastatic urothelial carcinoma of the bladder. Uroplakin II antibody [BC21] has
exhibited an increased sensitivity (46/59, 78%) when compared to Uroplakin III
[AU1] (191/56, 34%) in cases of urothelial carcinoma of the bladder with the
exception of bladder and ureter, staining was highly specific in various normal
and neoplastic tissues in an in-house study. Uroplakin II antibody [BC21] is a
highly specific antibody that may be useful in identifying tumors of urothelial
origin. PATENT PENDING.
1. Wu XR, et al. Uroplakins in urothelial biology, function, and disease.
Kidney Int. 2009 Jun; 75(11):1153-65.
2. Wu X, et al. Uroplakin II as a
promising marker for molecular diagnosis of nodal metastases from bladder
cancer: comparison with cytokeratin 20. J Urol. 2005 Dec; 174(6):2138-42.
Lu JJ, et al. Detection of circulating cancer cells by reverse
transcription-polymerase chain reaction for uroplakin II in peripheral blood of
patients with urothelial cancer. Clin Cancer Res. 2000 Aug; 6(8):3166-71.
Li SM, et al. Detection of circulating uroplakin-positive cells in patients with
transitional cell carcinoma of the bladder. J Urol. 1999 Sep; 162(3 Pt
5. Center for Disease Control Manual. Guide: Safety Management, NO.
CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains
to Remove Azide Salts.”
6. Clinical and Laboratory Standards Institute
(CLSI). Protection of Laboratory workers from occupationally Acquired
Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA